Iluvien implant is used in the treatment chronic diabetic macular oedema vision impairment, where available therapies have not been effective.
One implant of Iluvien as a single dose is given only into the affected eye. Iluvien produces an ongoing release of the active ingredient for up to 36 months.
Information about Iluvien Implant (Fluocinolone)
Iluvien is a sustained-release implant containing fluocinolone acetonide, a corticosteroid. It is designed for intravitreal injection, allowing for localized delivery of the medication to treat retinal conditions. The implant releases the drug over an extended period, typically up to 36 months.
Product Highlights
- Iluvien is primarily indicated for:
- Treatment of chronic diabetic macular edema (DME) in patients who are not responsive to other therapies.
- Other conditions related to retinal inflammation.
Key Ingredient
Key Benefits
- Helps decrease fluid accumulation in the retina, improving vision.
- The slow release of fluocinolone provides continuous therapeutic effects.
- Many patients see stabilization or enhancement in their visual acuity.
Direction of Use
- The implant is inserted into the eye by an ophthalmologist using a specific insertion device.
- Typically administered once every 36 months, depending on patient response and condition.
Safety Concerns
- Can increase, leading to glaucoma; monitoring is necessary.
- There is a potential for endophthalmitis or other ocular infections.
- Prolonged use is associated with a higher risk of cataract formation.
Avoid Iluvien Implant (Fluocinolone) If
- Patients with current infections should avoid the implant.
- Individuals with known allergies to fluocinolone or any component of the implant.
- Patients with poorly managed intraocular pressure should not use Iluvien.
